Insys execs guilty of opioid racketeering scheme

Insys Therapeutics founder John Kapoor and four other executives were convicted May 2 of a racketeering conspiracy that boosted sales of a highly addictive opioid, helping drive the opioid crisis in the U.S., according to Reuters.

Advertisement

With the guilty verdict, Mr. Kapoor becomes the first pharmaceutical CEO convicted in a case tied to the opioid epidemic. Mr. Kapoor was arrested the day President Donald Trump declared the opioid epidemic a public health emergency.

Prosecutors said that Mr. Kapoor and four other executives conspired to bribe physicians with speaker fees to promote and prescribe its under-the-tongue fentanyl spray Subsys. In addition, prosecutors said Insys duped insurers into covering its Subsys prescriptions.

The jury verdict against Kapoor came on the 15th day of deliberations. The trial lasted 10 weeks.

This marks a steep downfall for Mr. Kapoor, who worked his way up to start a company that turned into a multibillion dollar drugmaker.

The other Insys execs convicted were Insys’ former vice president Michael Gurry, ex-national sales director Richard Simon and former regional sales directors Joseph Rowan and Sunrise Lee.

Read more about the trial here.

 

More articles on pharmacy:
10 hospitals seeking pharmacy leaders
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody’s says

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

How Leading Pharmacies Stay Stocked And Protect Margins

Thursday, July 23
12:00 PM - 1:00 PM CDT

Presenters: Calvin Hunsicker, SureCostChad O’Connor, SureCost

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.